Iovance Biotherapeutics Inc
IOVA2.345USD
-0.025-1.05%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
801.80MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Iovance Biotherapeutics Inc Unternehmen
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Unternehmensinformationen
BörsenkürzelIOVA
Name des UnternehmensIovance Biotherapeutics Inc
IPO-datumJun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
Anzahl der mitarbeiter838
WertpapierartOrdinary Share
GeschäftsjahresendeJun 20
Addresse825 Industrial Road
StadtSAN CARLOS
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94070
Telefon16502607120
Websitehttps://www.iovance.com/
BörsenkürzelIOVA
IPO-datumJun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Dr. Friedrich Graf Finckenstein, M.D.
Dr. Friedrich Graf Finckenstein, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
48.52M
98.37%
Rest of world
804.00K
1.63%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
Andere
68.67%
Aktionäre
Aktionäre
Anteil
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
Andere
68.67%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
21.45%
Hedge Fund
16.62%
Investment Advisor/Hedge Fund
9.65%
Private Equity
8.01%
Venture Capital
7.77%
Research Firm
5.49%
Individual Investor
0.36%
Bank and Trust
0.25%
Pension Fund
0.18%
Andere
30.24%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
654
271.34M
81.00%
-28.55M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
MHR Fund Management LLC
24.42M
7.31%
--
--
Mar 31, 2025
Quogue Capital L.L.C.
28.07M
8.4%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
27.73M
8.3%
+243.44K
+0.89%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.54M
6.15%
+368.21K
+1.83%
Mar 31, 2025
Long Focus Capital Management LLC
9.25M
2.77%
+4.12M
+80.24%
Mar 31, 2025
State Street Global Advisors (US)
11.04M
3.31%
-1.21M
-9.86%
Mar 31, 2025
Invenomic Capital Management LP
5.49M
1.64%
+5.49M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
5.97M
1.79%
+96.88K
+1.65%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Name
Anteil
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Biotechnology ETF
0%
SPDR S&P Kensho New Economies Composite ETF
0%
Virtus LifeSci Biotech Products ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Russell 2000 ETF
0%
Mehr Anzeigen
Global X Russell 2000 ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
iShares Biotechnology ETF
Anteil0%
SPDR S&P Kensho New Economies Composite ETF
Anteil0%
Virtus LifeSci Biotech Products ETF
Anteil0%
JPMorgan BetaBuilders US Small Cap Equity ETF
Anteil0%
iShares Genomics Immunology and Healthcare ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Fidelity MSCI Health Care Index ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
